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Double ELISA costed #250 naira ($2) while Immunocomb 
II and Immunoconfirm costed #500 naira ($4). A total of 280 
sera were tested with 126 reactive while 258 sera were 
tested with 95 reactive in periods A and B respectively. 
Positive and negative controls from both the manufacturers 
kits and known positive hospital laboratory samples were 
used.
We collated and compared HIV antibodies tests results at 
the teaching hospital between period A and period B. A total 
of 547 sera, aseptical collected,separated, stored were then 
processed. Results obtained were analyzed using Chi square 
statistical method (analysis) and are presented below.
Results
The results obtained in periods A and B are presented below 
in tables I, II and III. 
Table I shows results obtained using Double ELISA. A total 
of 289 sera were tested and 126 sera were reactive with a 
total prevalence rate of the 43.1%.  Of the 289 sera, 172 
were from men while 117 were from women. 75 men and 51 
women were reactive respectively.
Table II shows that out of the 258 sera examined in Period B, 
172 were from men with a total of 63 positive sera while 86 
were women with a total of 32 positive sera. A total of 95 
sera were positive giving a prevalence rate of 36.8%.
Table III shows the AKTH charges during the two periods of 
study. Before the introduction of Immunoconfirmatory kit, 
N 250 ($2) were charged. After the introduction, N500 or $4 
were charged patients. X2 at 1 df P = 0.05 is highly 
significant.
Table IV shows that a total number of patients tested within 
the two periods to be 547. The overall prevalence rate was 
40.4% from 221 positive cases. The finding was significant. 
X2 at 1 df at P = 0.05 is significant.
Discussion
Our results show that from the introduction of 
Immunconfirmatory test kits, there was a doubling of the 
cost of HIV testing at the teaching hospital from two dollars 
or N250 naira to four dollars or N500 naira. This may have 
accounted for the drop in the number of patients who came 
for HIV antibody testing from 289 in period A to 258 in 
period B. A difference of 41 patients in two comparable 
periods. The second period also witnessed a reduction in the 
number of positive samples from a prevalence of 43.6% in 
period A to 36.8% in period B. HIV antibodies testing 
generally will either be reactive or non-reactive depending 
on the presence or absence of antibodies to HIV Protein (P) 
or glyco protein (gp) which include the group specific or 
core antigens (gag) P24 and P12, the envelope proteins, gp 
120/160 and gp 41, the polymerase (pol) proteins P31 and 
P66/51. There was a reduction in the number of positive 
cases when Immunoconfirmatory test was introduced. False 
positive results may have been recorded initially when there 
was absence of confirmatory tests. The causes of false 
positive ELISA may be due to the presence of Human 
leukocyte antigen (HLA) haplotypes, DR antigen in 
multiparous women, antoimmune disorders, multiple 
transfusion recipients, multiple myeloma, alcoholic 
hepatitis and recently influenza vaccination. Others include 
haemodialysis, mislabeled specimens and positive rapid 
plasma reagin (RPR) 2. These false positive reactions occur 
as a result of cross reacting antibodies. False negative are 
rarely observed but may occur if the patient recently 
acquired the HIV antigen and seroconversion has not taken 
place. Also in advanced HIV disease in which case the 
patient may have lost the ability to make HIV antibodies 
especially P24. The introduction of Immunoconfrimatory 
technique into HIV antibodies testing in this center brought 
about reliability of laboratory test results. Although the 
patients may have paid more for the investigation, as far as 
health care providers are concerned, the period brought both 
assurance and more confidence to HIV diagnosis.
Table 1: Results obtained using ELISA in Period A 
(November 1997 – May 1998)
Table 2: Results obtained in second period B 
(November 1998 – May 1999)
Table 3:Cost Distribution according to kits in the
 two Periods A and B
Table 4: Prevalence rates among hospital patients.
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Abstract
Background: When HIV antibodies testing was introduced in Aminu Kano Teaching Hospital, Kano a couple of years ago, 
Double ELISA was used to test blood samples before a particular specimen was diagnosed as reactive or non-reactive. A time 
came when immunoconfirmatory test was introduced into HIV antibodies testing for confirmations of the presence of HIV.
Objectives: This present retospective study is to review the impact of cost and quality of HIV reagent kits in the two periods A 
and B on the patients and confidence on the health care provider.
Methods: We collated and compared laboratory records for both periods of HIV antibodies testing at Aminu Kano Teaching 
Hospital Kano consisting of period A from November 1997 to May 1998 (7 months) and period B from November 1998 to May 
1999 (7months). In period A, double ELISA was used (Genie II and Immunocomb Bispot) while in period B, Immunocomb 
Bispot and Immunoconfirm II were used
Results: The results show that the cost per test increased from two hundred and fifty Naira($2) to five hundred Naira($4). 
There was a reduction on the number of patients from 289 to 258 within the two periods. But the prevalence of reactive HIV 
antibodies decreased from 43.6% to 36.8%.
Conclusion: The period when Immunoconfirmatory technique was introduced brought assurance, reliability and confidence 
to HIV diagnosis test in the centre.
Introduction
L a b o r a t o r y  t e s t i n g  o f  p a t i e n t s  f o r  H u m a n  
Immunodeficiency Virus (HIV) infection is an important 
tool in health for both patients and healthy individuals1. As 
the knowledge of HIV infection is increasing so also the 
complexity of laboratory tests for its detection is 
increasing2. Over 22 million people were estimated by the 
WHO to be infected with HIV in developing counties and 
most of which are in Sub-Sahara Africa as at year 1999-
20003,4. The first HIV antibodies detection technique was 
licensed in 1985 by the Food and Drug Administration 
(FDA) in America2,4. Since then several test kits have been 
produced and introduced into the world markets. When HIV 
antibodies testing was introduced many years ago, the 
World Health Organization (WHO) recommended that 
Double ELISA (techniques) be adopted by developing 
countries5,6 before a patient can be said to be positive for 
HIV infection. This was to avoid false results often 
associated with these technologies (first and second 
generation ELISA kits). As time went on, the government of 
Nigeria introduced a confirmatory test technique for more 
reliability of results. This present study therefore presents 
two periods A and B when the different techniques were 
introduced in our center and the effects on the patients and 
health care providers
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Figure 1: Algorithm for managing HIV-infected patients with acute CNS presentation
Table 1: CSF parameters in various pathological conditions
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Introduction
The World Health Organization (WHO) 2001 Global 
Burden of disease study has reported HIV/ADS as the 
leading cause of mortality in Sub-Saharan Africa, followed 
closely by malaria1. Of persons with HIV, more than 10% 
have neurologic dysfunction and 30% to 70% eventually 
develop neurological complications2.
HIV may affect the nervous system directly by producing 
distinct neurological syndromes, or indirectly by causing 
immunodeficiency with a resultant susceptibility to 
opportunistic infections. Central nervous system 
involvement is one of the common manifestations of 
acquired immunodeficiency syndrome (AIDS)3. The 
following CNS diseases are the commonly reported; 
Bacterial  Meningit is ,  tuberculous meningit is ,  
cryptococcosis, cytomegalovirus infection, human 
immunodeficiency encephalopathy, Primary CNS 
lymphoma (PCNSL) ,  P rogress ive  mul t i foca l  
leukoencephalopathy (PML) ,Vacuolar Myelopathy, 
Sensory Neuropathies  and toxoplasmosis, with low CD4 
count as the regular accompaniment of these disorders in 
developing countries5.
Pathphysiologically, HIV enters the nervous system early,   
after infection, and productive CNS infection is rarely 
established until systemic immunosuppression develops, 
probably after re-entry of HIV into CNS. Chronic immune 
activation with HIV disease progression leads to 
deregulation of macrophages, with the overproduction of 
various proinflammatory cytokines and chemokines within 
the CNS and peripheral nervous system5,6.
Clinical  Presentation
HIV-Dementia typically manifest with cognitive, 
behavioural, and motor dysfunction which are characteristic 
of sub-cortical dementia. In the early stages, short term 
memory loss, mental slowing, reading and comprehension 
difficulties appears. Gait disturbance, with stumbling and 
tripping, is common, and tremor and impairment of fine 
manual dexterity develops in most patients.  Other disorders 
that may also be seen in other diseases include: Headache, 
Fever, Meningism, Coma/altered consciousness Focal 
neurological deficits (hemiplegia, visual loss etc) and 
seizures, Delirium (acute confusional state) , Constitutional; 
malaise, lethargy, anorexia, nausea, vomiting, weight loss 
have all been reported7,8.  Dissemination   to the brain and 
meninges is the most common clinical manifestation of 
cryptococcosis  in about  75% to 90%; and these will 
manifest as meningitis, meningoencephalitis,  or a  
cryptococcoma mass9.
HIV-1-associated myelopathies is a slowly progressive 
painless spastic paraparesis, with sensory ataxia and 
neurogenic bladder. There are prominent vacuolar changes 
in the ascending and descending tracts that commonly affect 
the thoracic spinal cord. Risk factors for VM include high 
number of systemic AIDS-defining illnesses (such as 
pneumocystis carinii). Presence of sensory neuropathy is 
said to be commonly associated with Vacuolar myelopathy. 
Disturbances in vitamin B12-dependent transmethylation 
pathways may be related. It is said that CSF S-adenosyl 
methionine concentrations are reduced in VM7.
HIV-Sensory Neuropathy commonly manifest as pain. 
These are the distal sensory polyneuropathy and 
antiretroviral toxic neuropathy, caused by nucleoside 
reverse transcriptase inhibitors. The symptoms are usually 
symmetrical or bilateral, of gradual onset and described as 
aching, painful or burning. Motor neuropathy as a result of 
HIV-SN is quite rare10.
Diagnostic studies
There is currently no definitive or diagnostic CSF profile for 
HIV-D. CSF analysis may be important in febrile patients 
and who are acutely encephalopathic mainly to exclude 
cryptococcal or tuberculous meningitis. CSF findings 
includes; high concentrations of HIV RNA and signs of 
immune activation.  Some co-workers had reported positive 
correlations with increased HIV RNA and neurological 
complications in an untreated person with HIV/AIDS11.  
Various CSF markers of immune activation are also 
elaborated in HIV-D, and these include; neopterin, â2-
microglobulin, quinolinic acid, soluble Fas and protein 
carbonyls, they also correlate strongly with dementia 
severity [12, 13, 14, 15].  MRI imaging in HIV-D clearly 
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